Kidney Int Rep . Early administration of Anti-SARS-CoV-2 Monoclonal Antibodies prevents severe Covid-19 in Kidney Transplant Patients

[tetano]

Kidney Int Rep


. 2022 Mar 26.
doi: 10.1016/j.ekir.2022.03.020. Online ahead of print.
Early administration of Anti-SARS-CoV-2 Monoclonal Antibodies prevents severe Covid-19 in Kidney Transplant Patients


Juliette Gueguen ¹ , Charlotte Colosio ² , Arnaud Del Bello ³ , Anne Scemla ⁴ , Yohan N'Guyen ⁵ , Claire Rouzaud ⁶ , Claudia Carvalho-Schneider ⁷ , Gabriela Gautier Vargas ⁸ , Pierre Tremolières ⁹ , A Jalal Eddine ¹⁰ , Christophe Masset ¹¹ , Olivier Thaunat ¹² , Melchior Chabannes ¹³ , Paulo Malvezzi ¹⁴ , Pierre Pommerolle ¹⁵ , Lionel Couzi ¹⁶ , Nassim Kamar ³ , Sophie Caillard ⁸ , Philippe Gatault ¹



Affiliations

• PMID: 35372734
• PMCID: PMC8957354
• DOI: 10.1016/j.ekir.2022.03.020

Abstract

Kidney transplant recipients (KTRs) are prone to develop severe coronavirus disease 2019 (Covid-19) and are less well protected by vaccine than immunocompetent subjects. Thus, the use of neutralizing monoclonal anti-SARS-CoV-2 antibody (MoAb) to confer a passive immunity appears attractive in KTRs.
Methods: We performed a French nation-wide study to compare Covid-19-related hospitalization, 30-days-admission to intensive care unit (ICU) and 30-days-death between KTRs who received an early infusion of MoAb (MoAb group) and KTRs who did not (control group). Controls were identified from the COVID-SFT registry (NCT04360707) using a propensity score matching with the following covariates: age, sex, delay between transplantation and infection, induction and maintenance immunosuppressive therapy, initial symptoms and comorbidities.
Results: Eighty KTRs received MoAb between February and June 2021. They were matched to 155 controls. Covid-19-related hospitalization, 30-days-admission to intensive care unit (ICU) and 30-days-death were less frequently observed in MoAb group (35.0% vs 49.7%, p=0.032; 2.5% vs 15.5%, p=0.002, 1.25% vs 11.6%, p=0.005, respectively). No patients required mechanical ventilation in MoAb group. The number of patients to treat to prevent one death was 9.7.
Conclusion: The early use of MoAb in KTRs with a mild form of Covid-19 largely improved outcomes in KTRs.

Keywords: BMI, body mass index; CNI, calcineurin inhibitor; COVID-19; Covid-19, coronavirus disease 2019; EMA, European Medicines Agency; FDA, Food and Drug Administration; HIV, human immunodeficiency virus; ICU, intensive care unit; IQR, interquartile range; KTR, kidney transplant recipient; MoAb, monoclonal antibody; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; SOT, solid organ transplant; mTOR, mammalian target of rapamycin; monoclonal antibody; rt-PCR, real-time polymerase chain reaction; transplantation; viral infection.

[sharon sanders]

bump this